Clinical Trial Update: Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports the combination of selumetinib and MK-2206 in patients with stage III/IV melanoma after progression on vemurafenib or dabrafen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MK-2206 (MK-2206)
• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2014-06-18